We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

58 hedge funds and large institutions have $108M invested in VanEck Pharmaceutical ETF in 2014 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

367% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 3

50% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 12

18% more funds holding

Funds holding: 49 → 58 (+9)

2.71% more ownership

Funds ownership: 30.18% → 32.9% (+2.7%)

11% less capital invested

Capital invested by funds: $121M → $108M (-$13.9M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
58
Holders Change
+9
Holders Change %
+18.37%
% of All Funds
1.55%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
14
Increased
18
Reduced
12
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AHS
Aspiriant Holdings S3
California
+$3.87M
2
ACM
Aviance Capital Management
Florida
+$2.52M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.32M
4
CS
Credit Suisse
Switzerland
+$2.22M
5
SG Americas Securities
SG Americas Securities
New York
+$1.87M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$18.6M
2
Barclays
Barclays
United Kingdom
-$15.8M
3
NCM
Niemann Capital Management
Nevada
-$7.32M
4
Bank of America
Bank of America
North Carolina
-$2.09M
5
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$1.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
26
Niemann Capital Management
Nevada
$835K -$7.32M -114,870 -90%
Millennium Management
27
Millennium Management
New York
$805K +$798K +12,523 New
KIA
28
KCM Investment Advisors
California
$572K – – –
LCM
29
LVM Capital Management
Michigan
$459K -$32.2K -505 -7%
Creative Planning
30
Creative Planning
Kansas
$447K +$441K +6,920 +23,067%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$437K – – –
RG
32
Redmile Group
California
$418K – – –
BPC
33
Banque Pictet & Cie
Switzerland
$411K – – –
FPCM
34
Financial Partners Capital Management
New York
$375K -$12.7K -200 -3%
Bank of Montreal
35
Bank of Montreal
Ontario, Canada
$331K -$25.5K -400 -7%
Wells Fargo
36
Wells Fargo
California
$321K +$255K +4,000 +400%
KFC
37
Klingenstein Fields & Co
New York
$308K – – –
JWM
38
Jacobus Wealth Management
Wisconsin
$306K – – –
VKH
39
Virtu KCG Holdings
New York
$270K +$268K +4,200 New
CCT
40
Country Club Trust
Missouri
$258K +$256K +4,020 New
FMW
41
Farr Miller & Washington
District of Columbia
$257K – – –
OPCM
42
Osborne Partners Capital Management
California
$244K – – –
RCG
43
Ruggie Capital Group
Florida
$232K +$230K +3,605 New
LTFS
44
Ladenburg Thalmann Financial Services
Florida
$229K -$10.1K -158 -4%
MFS
45
MSI Financial Services
Massachusetts
$200K +$86.4K +1,356 +77%
MA
46
MUFG Americas
New York
$165K – – –
PNC Financial Services Group
47
PNC Financial Services Group
Pennsylvania
$133K – – –
TCM
48
Tradewinds Capital Management
Washington
$129K -$7.64K -120 -6%
GT
49
Glenmede Trust
Pennsylvania
$77K – – –
Deutsche Bank
50
Deutsche Bank
Germany
$64K +$573 +9 +0.9%
1
2
3

PPH Hedge Fund Activity: Q4 2014 in Review

58 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2014, worth a combined $108M — down 11% from $121M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PPH positions and 3 closed out — a net gain of 11 holders — while 18 added to existing stakes and 12 trimmed.

The largest buyer was Aspiriant Holdings S3, opening a new position worth an estimated $3.87M. The largest seller was Goldman Sachs, cutting an estimated $18.6M.

  • 58 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2014, up from 49 in Q3 2014.
  • Funds reported $108M of VanEck Pharmaceutical ETF stock for Q4 2014, down 11% quarter-over-quarter.
  • 14 funds opened new VanEck Pharmaceutical ETF positions in Q4 2014 and 3 closed out, a net change of +11 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q4 2014 was Aspiriant Holdings S3, an estimated $3.87M added.
  • The largest VanEck Pharmaceutical ETF seller in Q4 2014 was Goldman Sachs, an estimated $18.6M sold.

Based on aggregated 13F filings for Q4 2014.